Clinical Trials

Phase 1 Active not recruiting

134 enrolled

Head & NeckLymphoid

Squamous Cell Carcinoma of Head and Neck, Lymphoma

NCT04521686 2025-06-27

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

200 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

Breast Neoplasms, Chondrosarcoma, Colonic Neoplasms, Glioblastoma, Glioma, Melanoma, Prostatic Neoplasms, Thyroid Neoplasms, Central Nervous System Neoplasms, Cholangiocarcinoma

NCT04613492 2025-06-24

A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors

40 enrolled

Solid Tumors

NCT04870112 2025-04-17

SCope-D1

18 enrolled

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT03509012 2025-01-14

CLOVER

105 enrolled

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT04504669 2024-11-05

First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

BreastDermatologicGenitourinaryGynecologicThoracic

60 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03946800 2024-10-02

A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors

61 enrolled

Tumor-Agnostic

Neoplasms

NCT02616640 2024-09-19

A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

114 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT03421353 2024-08-21

AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer

76 enrolled

Advanced Solid Tumours

NCT03238027 2024-05-17

A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors

45 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT02301130 2024-04-25

Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors

64 enrolled

Advanced Solid Tumors

NCT02718911 2023-10-16

A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors

72 enrolled 23 charts

Solid Tumor

NCT02503774 2023-07-11

MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.

192 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02740985 2023-05-26

A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

GastrointestinalGenitourinaryThoracic

313 enrolled

Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms, Colorectal Neoplasms

NCT03889275 2023-02-21

A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors

39 enrolled

Advanced Solid Tumors

NCT04261075 2022-08-15

IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.

57 enrolled

Advanced Solid Tumors

NCT02088112 2022-04-04

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).

56 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03665129 2022-01-27

STELLAR-001

73 enrolled

Advanced Solid Tumors

NCT03685344 2021-10-26

Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

13 enrolled 15 charts

Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT03056599 2021-09-24

Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma

23 enrolled

Sarcoma

NCT02978482 2021-08-18

A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies

26 enrolled

Advanced Malignancy

NCT01938612 2021-03-12

A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours

GastrointestinalHead & Neck

269 enrolled

Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms

NCT02572687 2021-01-20

A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies

85 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Neoplasm Metastasis, Stomach Neoplasms

NCT02900157 2021-01-14

Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors

42 enrolled

Advanced Solid Tumors

NCT02658214 2020-08-20

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

BreastGastrointestinalGynecologicHead & NeckThoracic

32 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03089645 2020-07-27

MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.

39 enrolled

Advanced Solid Tumors

NCT02261220 2020-03-06

A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors

380 enrolled

Advanced Solid Tumors

NCT02586987 2019-11-18

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

BreastDermatologicGastrointestinalThoracic

58 enrolled

Biliary Tract Neoplasms, Breast Neoplasms, Lung Neoplasms, Melanoma, Colorectal Neoplasms, Disease Progression

NCT02000947 2019-10-31

D4190C00006

459 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02705482 2019-08-26

A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors

58 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms

NCT02737072 2019-08-12

A Study of LY2510924 and Durvalumab in Participants With Solid Tumors

9 enrolled 13 charts

Solid Tumor

NCT02734160 2019-08-05

A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer

37 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT03394144 2019-06-24

Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies

11 enrolled

Advanced Solid Malignancies

NCT02027961 2019-05-17

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone